Nevada lawmaker urges Purdue to unveil prescribers list; GSK splits U.K., Ireland business ahead of drink brands sale;

@FiercePharma: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Article | Follow @FiercePharma

@EricPFierce: India to consider putting handcuffs on foreign investment to protect domestic generics market. Story | Follow @EricPFierce

@CarlyHFierce: Merck stops selling Zilmax to study livestock drug's safety; the drug added $159M to sales in 2012. News | Follow @CarlyHFierce

> Nevada State Sen. Richard Segerblom has joined calls for Purdue Pharma to hand over a list of doctors suspected of recklessly prescribing its addictive painkiller OxyContin. Report

> GlaxoSmithKline ($GSK) has split its U.K. and Ireland businesses and named leadership teams for each to prepare for its planned divestment of the drink brands Lucozade and Ribena. Report

> Health Canada has approved ThromboGenics' eye drug Jetrea to treat symptomatic vitreomacular adhesion. Report

> India's Lupin is looking for branded drugs to buy in the United States. Report

> A Novartis ($NVS) executive in India scolded the country's recent intellectual property moves, saying the revocation of patents and issuance of compulsory licenses creates uncertainty and undermines R&D investment. Report

Medical Device News

@FierceMedDev: Special report: Device-tax worries aside, major med tech mostly added jobs in 2012. Feature | Follow @FierceMedDev

@DamianFierce: How can early-phase CROs brave a tough market? We asked two of the biggest. Editor's corner | Follow @DamianFierce

@MarkHFierce: Orthofix is in trouble again, this time for not filing its financials on time. Press release | Follow @MarkHFierce

@MichaelGFierce: Last week's Chutes & Ladders roundup: Pharma veteran Jeffrey Jonas takes top spot at Sage & more in biotech/pharma hirings. More | Follow @MichaelGFierce

> Abbott closes $250M deal for eye surgery biz. Article

> St. Jude snags Endosense for up to $331M. Report

> Cigna policy change risks hammering Myriad's Dx bottom line. Story

Biotech News

@FierceBiotech: Will the biotech dealmaking lull extend through the rest of the year? More | Follow @FierceBiotech

@JohnCFierce: Novartis lashes out at India's patent rulings, says country is losing R&D. But India clearly doesn't care about R&D. More | Follow @JohnCFierce

@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. Article | Follow @RyanMFierce

@EmilyMFierce: Inovio vaccine kills malaria, boosts immune response in animals. Story | Follow @EmilyMFierce

> GTx shares eviscerated after muscle drug flops in PhIII cancer studies. Story

> New DMD data gives Sarepta an edge in GlaxoSmithKline showdown. Article

> Analyst lays out worst-case scenario for Dendreon. Item

CRO News

> Quintiles buying Novella with eye on emerging biotechs. More

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Article

> Risk-based monitoring could be a boon to CROs. Item

> Boehringer pulls plug on VA commercial plant. Story

> Express Scripts sells CRO biz to private equity outfit. More

> WuXi ratchets up expectations after banner quarter. News

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Report

Biotech IT News

> RTI wins NIH support to advance web-based toolkit for genetics research. News

> India's InterpretOmics scores $1.6M round to fuel bioinformatics biz. Report

> Pfizer taps online marketplace for outsourcing research. Story

> FDA's former IT boss nails down industry gig. More

> Certara, provider of drug research software, buys Michigan rival. Article

And Finally... The U.S. obesity rate is growing more slowly than in years past, but "extreme" obesity has risen dramatically. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.